ipharmaservicesOct 14AstraZeneca and Daiichi Sankyo’s drug, Enhertu approved in China for HER2-mutant mNSCLC | iPharmaCenter
ipharmaservicesAug 24China's NMPA Grants Approval for Padcev (Enfortumab Vedotin) for Advanced Urothelial Cancer | iPharmaCenter
ipharmaservicesAug 13Enhertu Receives Conditional Approval in China for Advanced HER2-Positive Gastric Cancer | iPharmaCenter
ipharmaservicesJul 8HUTCHMED's NDA for Tazemetostat in China Receives Priority Review for Relapsed/Refractory Follicular Lymphoma | iPharmaCenter
ipharmaservicesJul 2Leqembi Launched in China for Treating Alzheimer's Disease | 2024 | iPharmaCenter
ipharmaservicesJun 26China Approves Tagrisso Combined with Chemotherapy as First-Line Treatment for Advanced EGFR-Mutated Lung Cancer | 2024 | iPharmaCenter
ipharmaservicesDec 31, 2023China Drug Approvals | 2023 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter
ipharmaservicesMar 16, 2023China Drug Approvals | 2022 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter
